Modern affinity reagents: Recombinant antibodies and aptamers

Biotechnology Advances

Volumn 33, Issue 8, 2015, Pages 1787-1798

  Groff, Katherine ^a   Brown, Jeffrey ^a   Clippinger, Amy J ^a  

^a PETA International Science Consortium Ltd   (United Kingdom)

Author keywords

Affinity reagents; Antibodies; Aptamers; Ascites antibodies; Recombinant antibodies

Indexed keywords

ANIMALS; MONOCLONAL ANTIBODIES; NUCLEIC ACIDS; RECOMBINANT PROTEINS; SURFACE PLASMON RESONANCE;

AFFINITY REAGENTS; APTAMERS; BASIC AND APPLIED RESEARCH; FEDERAL INCENTIVES; MONOCLONAL ANTIBODY PRODUCTION; NATIONAL ACADEMY OF SCIENCE; RECOMBINANT ANTIBODY; SCIENTIFIC RESEARCHES;

ANTIBODIES;

ANIMALIA;

ANTIBODY; NUCLEIC ACID; PROTEIN; RESEARCH WORK;

ANTIBODY; APTAMER; RECOMBINANT PROTEIN;

ANIMAL; BIOSYNTHESIS; GENETICS; IMMUNOLOGY; METABOLISM; SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT APTAMER TECHNIQUE;

ANIMALS; ANTIBODIES; APTAMERS, NUCLEOTIDE; RECOMBINANT PROTEINS; SELEX APTAMER TECHNIQUE;

EID: 84961924006     PISSN: 07349750     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biotechadv.2015.10.004     Document Type: Review

References (157)

1. Ahmadvand D., Rahbarizadeh F., Moghimi S.M. Biological targeting and innovative therapeutic interventions with phage-displayed peptides and structured nucleic acids (aptamers). Curr. Opin. Biotechnol. 2011, 22:832-838.
2. Alsager O.A., Kumar S., Zhu B., Travas-Sejdic J., McNatty K.P., Hodgkiss J.M. Ultrasensitive colorimetric detection of 17beta-estradiol: the effect of shortening DNA aptamer sequences. Anal. Chem. 2015, 87:4201-4209.
3. Altshuler E.P., Serebryanaya D.V., Katrukha A.G. Generation of recombinant antibodies and means for increasing their affinity. Biochemistry 2010, 75:1584-1605.
4. Amaya-González S., de-los-Santos-Alvarez N., Miranda-Ordieres A.J., Lobo-Castañón M.J. Aptamer-based analysis: a promising alternative for food safety control. Sensors (Basel) 2013, 13:16292-16311.
5. Animal Welfare Division of OPRR Production of Monoclonal Antibodies Using Mouse Ascites Method. NIH Document Number 98-01 1997.
6. Aquino-Jarquin G., Toscano-Garibay J.D. RNA aptamer evolution: two decades of SELEction. Int. J. Mol. Sci. 2011, 12:9155-9171.
7. Archemix Corp. United States Securities and Exchange Commission Amendment No. 7 to Form S-1 Registration Statement Under the Securities Act of 1933. Washington, DC 2008.
8. AxioMx Our technologies (Accessed March 6). http://axiomxinc.com/technology/our-technologies/.
9. Ayriss J., Woods T., Bradbury A., Pavlik P. High-throughput screening of single-chain antibodies using multiplexed flow cytometry. J. Proteome Res. 2007, 6:1072-1082.
10. Baird G.S. Where are all the aptamers?. Am. J. Clin. Pathol. 2010, 134:529-531.
11. Baker M. Reproducibility crisis: blame it on the antibodies. Nature 2015, 521:274-276.
12. Banerjee J., Nilsen-Hamilton M. Aptamers: multifunctional molecules for biomedical research. J. Mol. Med. 2013, 91:1333-1342.
13. Bannantine J.P., Radosevich T.J., Stabel J.R., Sreevatsan S., Kapur V., Paustian M.L. Development and characterization of monoclonal antibodies and aptamers against major antigens of Mycobacterium avium subsp. paratuberculosis. Clin. Vaccine Immunol. 2007, 14:518-526.
14. Barkhordarian H., Emadi S., Sierks M. Isolating recombinant antibodies against specific protein morphologies using atomic force microscopy and phage display technologies. Protein Eng. Des. Sel. 2006, 19:497-502.
15. Berglund L., Bjorling E., Oksvold P., Fagerberg L., Asplund A., Al-Khalili Sziguarto C., et al. A genecentric human protein atlas for expression profiles based on antibodies. Mol. Cell. Proteomics 2008, 7:2019-2027.
16. Boder E.T., Midelfort K.S., Wittrup K.D. Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. PNAS 2000, 97:10701-10705.
17. Bouchard P.R., Hutabarat R.M., Thompson K.M. Discovery and development of therapeutic aptamers. Annu. Rev. Pharmacol. Toxicol. 2010, 50:237-257.
18. Bradbury A., Plückthun A. Reproducibility: standardize antibodies used in research. Nature 2015, 518:27-29.
19. Bunka D.H.J., Platonova O., Stockley P.G. Development of aptamer therapeutics. Curr. Opin. Pharmacol. 2010, 10:557-562.
20. Canadian Council on Animal Care Guidelines on: Antibody Production 2002.
21. Casey J.L., Coley A.M., Tilley L.M., Foley M. Green fluorescent antibodies: novel in vitro tools. Protein Eng. 2000, 13:445-452.
22. Center for Drug Evaluation and Research Center for Drug Evaluation and Research Application Number 125370 Summary Review 2011.
23. Center for Drug Evaluation and Research Center for Drug Evaluation and Research Application Number 125349Orig1s000 Summary Review 2012, FDA.
24. Chen G., Sidhu S.S. Design and generation of synthetic antibody libraries for phage display. Monoclonal Antibodies 2014, 113-131. Humana Press, Totowa, NJ. V. Ossipow, N. Fischer (Eds.).
25. Cho SJ, Woo HM, Kim K-S, Oh J-W, Jeong YJ. Novel system for detecting SARS coronavirus nucleocapsid protein using an ssDNA aptamer. J. Biosci. Bioeng. 2011;112:e1347-e4421.
26. Citartan M., Gopinath S.C.B., Tominaga J., Tan S.-C., Tang T.-H. Assays for aptamer-based platforms. Biosens. Bioelectron. 2012, 34:1-11.
27. Clementi N., Mancini N., Solforosi L., Castelli M., Clementi M., Burioni R. Phage display-based strategies for cloning and optimization of monoclonal antibodies directed against human pathogens. Int. J. Mol. Sci. 2012, 13:8273-8292.
28. Collins F.S., Tabak L.A. Policy: NIH plans to enhance reproducibility. Nature 2014, 505:612-613.
29. Coomber D.W.J. Panning of Antibody Phage-Display Libraries: Standard Protocols. Antibody Phage Display 2001, 133-145. Humana Press, New Jersey.
30. Council of Europe Of the European Convention for the Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes (ETS No. 123) 2006, (Strasbourg).
31. Darmostuk M., Rimpelova S., Gbelcova H., Ruml T. Current approaches in SELEX: an update to aptamer selection technology. Biotechnol. Adv. 2015.
32. Dassie J.P., Giangrande P.H. Current progress on aptamer-targeted oligonucleotide therapeutics. Ther. Deliv. 2013, 4:1527-1546.
33. de Geus B., Hendriksen C.F. In vivo and in vitro production of monoclonal antibodies: current possibilities and future perspectives. Introduction. Res. Immunol. 1998, 149:533-534.
34. De Souza E.B., Cload S.T., Pendergrast P.S., Sah D.W. Novel therapeutic modalities to address nondrugable protein interaction targets. Neuropsychopharmacology 2009, 34:142-158.
35. Deng B., Lin Y., Wang C., Li F., Wang Z., Zhang H., et al. Aptamer binding assays for proteins: the thrombin example-a review. Anal. Chim. Acta 2014, 837:1-15.
36. Department for Environment Food and Rural Affairs. Development of aptamer-based technology to detect residues of veterinary drugs, and constituents of vaccines - VM02162. (Accessed March 10, 2015). http://randd.defra.gov.uk/Default.aspx?Menu=Menu&Module=More&Location=None&Completed=2&ProjectID=16304.
37. Donzeau M., Knappik A. Recombinant monoclonal antibodies. Monoclonal Antibodies 2007, 15-31. Humana Press, Totowa, NJ. M. Albitar (Ed.).
38. Dozier S. Special Section: Monoclonal Antibodies Altweb, Accessed February 17, 2015. http://altweb.jhsph.edu/mabs/mabs.html.
39. Echko M., Dozier S. Recombinant Antibody Technology for the Production of Antibodies Without the Use of Animals AltTox.org, (Accessed February 17, 2015). http://www.alttox.org/ttrc/emerging-technologies/cell-based/way-forward/echko-dozier/.
40. Eisenhardt S.U., Schwarz M., Bassler N., Peter K. Subtractive single-chain antibody (scFv) phage-display: tailoring phage-display for high specificity against function-specific conformations of cell membrane molecules. Nat. Protoc. 2007, 2:3063-3073.
41. Ellington A.D., Szostak J.W. In vitro selection of RNA molecules that bind specific ligands. Nature 1990, 346:818-822.
42. Esposito C.L., Catuogno S., de Franciscis V. Aptamer-mediated selective delivery of short RNA therapeutics in cancer cells. J. RNAi Gene Silenc. 2014, 10:500-506.
43. European Parliament OJ on the Protection of Animals Used for Scientific Purposes 2010, (2010/63/EU).
44. Even-Desrumeaux K., Chames P. Phage display and selections on cells. Antibody Engineering 2012, 225-235. Humana Press, Totowa, NJ. P. Chames (Ed.).
45. Feng H., Beck J., Nassal M., Hu K.-H. A SELEX-screened aptamer of human hepatitis B virus RNA encapsidation signal suppresses viral replication. PLoS One 2011, 6:e27862. (-e).
46. Foote J., Eisen H.N. Kinetic and affinity limits on antibodies produced during immune responses. PNAS 1995, 92:1254-1256.
47. Foote J., Eisen H.N. Breaking the affinity ceiling for antibodies and T cell receptors. PNAS 2000, 97:10679-10681.
48. Frenzel A., Kügler J., Wilke S., Schirrmann T., Hust M. Construction of human antibody gene libraries and selection of antibodies by phage display. Methods Mol. Biol. 2014, 1060:215-243.
49. Gao J., Sidhu S.S., Wells J.A. Two-state selection of conformation-specific antibodies. PNAS 2009, 106:3071-3076.
50. Gao Y., Yu X., Xue B., Zhou F., Wang X., Yang D., et al. Inhibition of hepatitis C virus infection by DNA aptamer against NS2 protein. PLoS One 2014, 9.
51. Geyer C.R., McCafferty J., Dubel S., Bradbury A.R., Sidhu S.S. Recombinant antibodies and in vitro selection technologies. Methods Mol. Biol. 2012, 901:11-32.
52. Gold L., Ayers D., Bertino J., Bock C., Bock A., Brody E.N., et al. Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One 2010, 5.
53. Gopinath S.C., Misono T.S., Kawasaki K., Mizuno T., Imai M., Odagiri T., et al. An RNA aptamer that distinguishes between closely related human influenza viruses and inhibits haemagglutinin-mediated membrane fusion. J. Gen. Virol. 2006, 87:479-487.
54. Hairul Bahara N.H., Tye G.J., Choong Y.S., Ong E.B.B., Ismail A., Lim T.S. Phage display antibodies for diagnostic applications. Biologicals 2013, 41:209-216.
55. Hanes J., Schaffitzel C., Knappik A., Pluckthun A. Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display. Nat. Biotechnol. 2000, 18:1287-1292.
56. Harel Inbar N., Benhar I. Selection of antibodies from synthetic antibody libraries. Arch. Biochem. Biophys. 2012, 526:87-98.
57. Harper K., Ziegler A. Recombinant Antibodies: Applications in Plant Science and Plant Pathology 1999, CRC Press.
58. Hendriksen C.F. Replacement, reduction and refinement in the production and quality control of immunobiologicals. AATEX 2006, 11:155-161.
59. Hendriksen C.F., de Leeuw W. Production of monoclonal antibodies by the ascites method in laboratory animals. Res. Immunol. 1998, 149:535-542.
60. Hoffhines A.J., Damoc E., Bridges K.G., Leary J.A., Moore K.L. Detection and purification of tyrosine-sulfated proteins using a novel anti-sulfotyrosine monoclonal antibody. J. Biol. Chem. 2006, 281:37877-37887.
61. Holliger P., Hudson P.J. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 2005, 23:1126-1136.
62. Home Office Annual Statistics of Scientific Procedure on Living Animals Great Britain 2013 2014, 42. (Table 7).
63. Hong H., Goel S., Zhang Y., Cai W. Molecular imaging with nucleic acid aptamers. Curr. Med. Chem. 2011, 18:4195-4205.
64. Howard G.C., Kaser M.R. Making and Using Antibodies: a Practical Handbook, Second Edition 2013, CRC Press.
65. Hu W.G., Jager S., Chau D., Chau D., Mah D., Mah D., et al. Generation of a recombinant full-length human antibody binding to botulinum neurotoxin A. Appl. Biochem. Biotechnol. 2010, 160:1206-1216.
66. Ilgu M., Wang T., Lamm M.H., Nilsen-Hamilton M. Investigating the malleability of RNA aptamers. Methods 2013, 63:178-187.
67. Jackson L.R., Trudel L.J., Fox J.G., Lipman N.S. Monoclonal antibody production in murine ascites I. Clinical and pathologic features. Lab. Anim. Sci. 1999, 49:70-80.
68. Keefe A.D., Pai S., Ellington A. Aptamers as therapeutics. Nat. Rev. Drug Discov. 2010, 9:537-550.
69. Kehoe J.W., Velappan N., Walbolt M., Rasmussen J., King D., Lou J., et al. Using phage display to select antibodies recognizing post-translational modifications independently of sequence context. Mol. Cell. Proteomics 2006, 5:2350-2363.
70. Kierny M.R., Cunningham T.D., Kay B.K. Detection of biomarkers using recombinant antibodies coupled to nanostructured platforms. Nano Rev. 2012, 3.
71. Köhler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256:495-497.
72. Kong H.Y., Byun J. Nucleic Acid aptamers: new methods for selection, stabilization, and application in biomedical science. Biomol. Ther. (Seoul) 2013, 21:423-434.
73. Kotlan B., Glassy M.C. Antibody phage display: overview of a powerful technology that has quickly translated to the clinic. Antibody Phage Display 2009, 1-15. Humana Press, Totowa, NJ. R. Aitken (Ed.).
74. Lakhin A.V., Tarantul V.Z., Gening L.V. Aptamers: problems, solutions and prospects. Acta Nat. 2013, 5:34-43.
75. Lao Y.H., Phua K.K., Leong K.W. Aptamer nanomedicine for cancer therapeutics: barriers and potential for translation. ACS Nano 2015, 9:2235-2254.
76. Lazzarotto T., Maine G.T., Dal Monte P., Ripalti A., Landini M.P. A novel Western blot test containing both viral and recombinant proteins for anticytomegalovirus immunoglobulin M detection. J. Clin. Microbiol. 1997, 35:393-397.
77. Lee G.H., Hah S.S. Coomassie blue is sufficient for specific protein detection of aptamer-conjugated chips. Bioorg. Med. Chem. Lett. 2012, 22:1520-1522.
78. Lee C.V., Liang W.C., Dennis M.S., Eigenbrot C., Sidhu S.S., Fuh G. High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold. J. Mol. Biol. 2004, 340:1073-1093.
79. Lev A., Denkberg G., Cohen C., Tzukerman M., Skorecki K., Chames P., Hoogenboom H., Reiter Y. Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit. Cancer Res. 2002, 62:3184-3194.
80. Li J., Tan S., Chen X., Zhang C.Y., Zhang Y. Peptide aptamers with biological and therapeutic applications. Curr. Med. Chem. 2011, 18:4215-4222.
81. Lloyd C., Lowe D., Edwards B., Welsh F., Dilks T., Hardman C., et al. Modelling the human immune response: performance of a 1011 human antibody repertoire against a broad panel of therapeutically relevant antigens. Protein Eng. Des. Sel. 2009, 22:159-168.
82. Lu Y., Liu J. Aptamer-Based Colorimetric Sensor Systems 2013, The Board Of Trustees Of The University Of Illinois.
83. Martin M.E., Garcia-Hernandez M., Garcia-Recio E.M., Gomez-Chacon G.F., Sanchez-Lopez M., Gonzalez V.M. DNA aptamers selectively target Leishmania infantum H2A protein. PLoS One 2013, 8.
84. Marx U., Merz W. In Vivo and In Vitro Production of Monoclonal Antibodies: Bioreactors Vs Immune Ascites. Monoclonal Antibody Protocols 1995, 169-176. Humana Press, New Jersey.
85. Marx U., Embleton M., Fischer R., Gruber F., Hansson U., Heuer J., et al. Monoclonal antibody production: the report and recommendations of ECVAM workshop 23. ATLA 1997, 25:121-137.
86. McArdle J. Alternatives to ascites production of monoclonal antibodies. Anim. Welf. Inf. Cent. Newsl. 1997, 8:15.
87. McCafferty J., Griffiths A., Winter G., Chiswell D. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990, 348(6301):552-554.
88. McGuill M.W., Rowan A.N. Refinement of monoclonal antibody production and animal well-being. ILAR J. 1989, 31:7-11.
89. McNutt M. Journals unite for reproducibility. Science 2014, 346:679.
90. Mersmann M., Meier D., Mersmann J., Helmsing S., Nilsson P., Graslund S., et al. Towards proteome scale antibody selections using phage display. New Biotechnol. 2010, 27:118-128.
91. Moutel S., Vielemeyer O., Jin H., Divoux S., Benaroch P., Perez F. Fully in vitro selection of recombinanat antibodies. Biotechnol. J. 2009, 4:38-43.
92. National Health and Medical Research Council Guidelines for Monoclonal Antibody Production 2008.
93. Nezlin R. Aptamers in immunological research. Immunol. Lett. 2014, 162:252-255.
94. Ni X., Castanares M., Mukherjee A., Lupold S.E. Nucleic acid aptamers: clinical applications and promising new horizons. Curr. Med. Chem. 2011, 18:4206-4214.
95. NIH Principles and guidelines for reporting preclinical research Bethesda, MD, (Accessed June 13, 2015). http://www.nih.gov/science/reproducibility/principles-guidelines.htm.
96. NIH Office of Animal Care and Use Guidelines for Ascites Production in Mice 1996, (Accessed February 4, 2015). http://oacu.od.nih.gov/ARAC/documents/Ascites.pdf.
97. Nixon A.E., Sexton D.J., Ladner R.C. Drugs derived from phage display. mAbs 2014, 6:73-85.
98. Nizak C., Monier S., del Nery E., Moutel S., Goud B., Perez F. Recombinant antibodies to the small GTPase Rab6 as conformation sensors. Science 2003, 300:984-987.
99. Nizak C., Moutel S., Goud B., Perez F. Selection and application of recombinant antibodies as sensors of rab protein conformation. Methods Enzymol. 2005, 403:135-153.
100. Noma T., Ikebukuro K., Sode K., Ohkubo T., Sakasegawa Y., Hachiya N., et al. A screening method for DNA aptamers that bind to a specific, unidentified protein in tissue samples. Biotechnol. Lett. 2006, 28:1377-1381.
101. NRC Monoclonal Antibody Production. Report of the Committee on Methods for Producing Monoclonal Antibodies 1999, National Academy Press, Washington, D.C.
102. OECD Guidance Document on the Recognition, Assessment and Use of Clinical Signs as Humane Endpoints for Experimental Animals Used in Safety Evaluation 2002, Organisation for Economic Co-operation and Development, Paris.
103. Pan W., Clawson G.A. The shorter the better: reducing fixed primer regions of oligonucleotide libraries for aptamer selection. Molecules 2009, 14:1353-1369.
104. Parsons H.L., Earnshaw J.C., Wilton J., Johnson K.S., Schueler P.A., Mahoney W., et al. Directing phage selections towards specific epitopes. Protein Eng. 1996, 9:1043-1049.
105. Pavoni E., Vaccaro P., Anastasi A., Minenkova O. Optimized selection of anti-tumor recombinant antibodies from phage libraries on intact cells. Mol. Immunol. 2014, 57:317-322.
106. Pei X., Zhang J., Liu J. Clinical applications of nucleic acid aptamers in cancer. Mol. Clin. Oncol. 2014, 2:341-348.
107. Pendergrast P.S., Marsh H.N., Grate D., Healy J.M., Stanton M. Nucleic acid aptamers for target validation and therapeutic applications. J. Biomol. Tech. 2005, 16:224-234.
108. Penner G. Commercialization of an aptamer-based diagnostic test. IVD Technol. 2012, 18:31-37.
109. Pershad K., Pavlovic J.D., Graslund S., Nilsson P., Colwill K., Karatt-Vellatt A., et al. Generating a panel of highly specific antibodies to 20 human SH2 domains by phage display. Protein Eng. Des. Sel. 2010, 23:279-288.
110. Peterson N.C. Behavioral, clinical, and physiologic analysis of mice used for ascites monoclonal antibody production. Commun. Med. 2000, 50:516-526.
111. Petrenko V.A., Vodyanoy V.J. Phage display for detection of biological threat agents. J. Microbiol. Methods 2003, 53:253-262.
112. Ponsel D., Neugebauer J., Ladetzki-Baehs K., Tissot K. High affinity, developability and functional size: the holy grail of combinatorial antibody library generation. Molecules 2011, 16:3675-3700.
113. Prassler J., Thiel S., Pracht C., Polzer A., Peters S., Bauer M., et al. HuCAL PLATINUM, a synthetic Fab library optimized for sequence diversity and superior performance in mammalian expression systems. J. Mol. Biol. 2011, 413:261-278.
114. Purschke W.G., Hoehlig K., Buchner K., Zboralski D., Schwoebel F., Vater A., et al. Identification and characterization of a mirror-image oligonucleotide that binds and neutralizes sphingosine 1-phosphate, a central mediator of angiogenesis. Biochem. J. 2014, 462:153-162.
115. Rader C. Generation of Human Fab Libraries for Phage Display. Antibody Methods and Protocols 2012, 53-79. Humana Press, Totowa, NJ. G. Proetzel, H. Ebersbach (Eds.).
116. Radom F., Jurek P.M., Mazurek M.P., Otlewski J., Jeleń F. Aptamers: molecules of great potential. Biotechnol. Adv. 2013, 31:1260-1274.
117. Ramos E., Pineiro D., Soto M., Abanades D.R., Martin M.E., Salinas M., et al. A DNA aptamer population specifically detects Leishmania infantum H2A antigen. Lab. Investig. 2007, 87:409-416.
118. Ramos E., Moreno M., Martin M.E., Soto M., Gonzalez V.M. In vitro selection of Leishmania infantum H3-binding ssDNA aptamers. Oligonucleotides 2010, 20:207-213.
119. Ray P., Viles K.D., Soule E.E., Woodruff R.S. Application of aptamers for targeted therapeutics. Arch. Immunol. Ther. Exp. (Warsz) 2013, 61:255-271.
120. Razai A., Garcia-Rodriguez C., Lou J., Geren I.N., Forsyth C.M., Robles Y., et al. Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A. J. Mol. Biol. 2005, 351:158-169.
121. Robertson D.L., Joyce G.F. Selection in vitro of an RNA enzyme that specifically cleaves single-stranded DNA. Nature 1990, 344:467-468.
122. Rothlisberger D., Pos K.M., Pluckthun A. An antibody library for stabilizing and crystallizing membrane proteins - selecting binders to the citrate carrier CitS. FEBS Lett. 2004, 564:340-348.
123. Schier R., McCall A., Adams G.P., Marshall K.W., Merritt H., Yim M., et al. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J. Mol. Biol. 1996, 263:551-567.
124. Schirrmann T., Meyer T., Schütte M., Frenzel A., Hust M. Phage display for the generation of antibodies for proteome research, diagnostics and therapy. Molecules 2011, 16:412-426.
125. Scholler N. Selection of antibody fragments by yeast display. Methods Mol. Biol. 2012, 907:259-280.
126. Seymour S. Overview of the FDA Background Materials for BLA# 125277, Kalbitor (Ecallantide) Injection 30 mg, for the Treatment of Acute Attacks of Hereditary Angioedema (HAE) in Patients 10 Years of Age and Older 2009, FDA Division Memorandum.
127. Shin S., Kim I.H., Kang W., Yang J.K., Hah S.S. An alternative to Western blot analysis using RNA aptamer-functionalized quantum dots. Bioorg. Med. Chem. Lett. 2010, 20:3322-3325.
128. Shoemaker C.B. When will rAbs replace mAbs in labs?. Vet. J. 2005, 170:151-152.
129. Simmons S.C., McKenzie E.A., Harris L.K., Aplin J.D., Brenchley P.E., Velasco-Garcia M.N., et al. Development of novel single-stranded nucleic acid aptamers against the pro-angiogenic and metastatic enzyme heparanase (HPSE1). PLoS One 2012, 7.
130. Smith G.P. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985, 228:1315-1317.
131. Šmuc T., Ahn I.-Y., Ulrich H. Nucleic acid aptamers as high affinity ligands in biotechnology and biosensorics. J. Pharm. Biomed. Anal. 2013, 81-82:210-217.
132. Steidl S., Ratsch O., Brocks B., Dürr M., Thomassen-Wolf E. In vitro affinity maturation of human GM-CSF antibodies by targeted CDR-diversification. Mol. Immunol. 2008, 46:135-144.
133. Storz U. Intellectual property protection: strategies for future antibody inventions. mAbs 2011, 3:310-317.
134. Strehlitz B., Nikolaus N., Stoltenburg R. Protein detection with aptamer biosensors. Sensors (Basel) 2008, 8:11.
135. Sundaram P., Kurniawan H., Byrne M.E., Wower J. Therapeutic RNA aptamers in clinical trials. Eur. J. Pharm. Sci. 2013, 48:259-271.
136. Tan W., Wang H., Chen Y., Zhang X., Zhu H., Yang C., et al. Molecular aptamers for drug delivery. Trends Biotechnol. 2011, 29:634-640.
137. Taylor A.I., Arangundy-Franklin S., Holliger P. Towards applications of synthetic genetic polymers in diagnosis and therapy. Curr. Opin. Chem. Biol. 2014, 22C:79-84.
138. Ten Haaf A., Pscherer S., Fries K., Barth S., Gattenlöhner S., Kemal T.M. Phage display-based on-slide selection of tumor-specific antibodies on formalin-fixed paraffin-embedded human tissue biopsies. Immunol. Lett. 2015, 166:65-78.
139. Thie H., Voedisch B., Dübel S., Hust M., Schirrmann T. Affinity maturation by phage display. Therapeutic Antibodies 2009, 309-322. Humana Press, Totowa, NJ. A.S. Dimitrov (Ed.).
140. Thiviyanathan V., Gorenstein D.G. Aptamers and the next generation of diagnostic reagents. Proteomics Clin. Appl. 2012, 6:563-573.
141. Toh S.Y., Citartan M., Gopinath S.C.B., Tang T.-H. Aptamers as a replacement for antibodies in enzyme-linked immunosorbent assay. Biosens. Bioelectron. 2015, 64C:392-403.
142. Tuerk C., Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249:505-510.
143. Unkauf T., Miethe S., Fühner V., Schirrmann T., Frenzel A., Hust M. Generation of recombinant antibodies against toxins and viruses by phage display for Diagnostics and Therapy. Adv. Exp. Med. Biol. 2015, (in press).
144. Wandtke T., Wozniak J., Kopinski P. Aptamers in diagnostics and treatment of viral infections. Viruses 2015, 7:751-780.
145. Webber J.P., Stone T.C., Katilius E., Smith B.C., Gordon B., Mason M.D., et al. Proteomics analysis of cancer exosomes using a novel modified aptamer-based array (SOMAscan™) platform. Mol. Cell. Proteomics 2014, 13:1050-1064.
146. Weidanz J.A. Methods of Assaying Vaccine Potency 2014, Receptor Logic, Inc.
147. Xiao Z., Shangguan D., Cao Z., Fang X., Tan W. Cell-specific internalization study of an aptamer from whole cell selection. Chemistry 2008, 14:1769-1775.
148. Xu Y., Yang X., Wang E. Aptamers in microfluidic chips. Anal. Chim. Acta 2010, 683:12-20.
149. Yau K., Lee H., Hall J. Emerging trends in the synthesis and improvement of hapten-specific recombinant antibodies. Biotechnol. Adv. 2003, 21:599-637.
150. Ylera F. HuCAL Antibodies Technical Manual 2010, (Oxford, UK). second ed. MorphoSys UK Ltd. (Ed.).
151. Yue Q., Shen T., Wang J., Wang L., Xu S., Li H., et al. A reusable biosensor for detecting mercury(II) at the subpicomolar level based on "turn-on" resonance light scattering. Chem. Commun. (Camb.) 2013, 49:1750-1752.
152. Zaher H.S., Unrau P.J. Nucleic acid library construction using synthetic DNA constructs. Methods Mol. Biol. 2005, 288:359-378.
153. Zeng Z., Zhang P., Zhao N., Sheehan A.M., Tung C.H., Chang C.C., et al. Using oligonucleotide aptamer probes for immunostaining of formalin-fixed and paraffin-embedded tissues. Mod. Pathol. 2010, 23:1553-1558.
154. Zhang Y., Hong H., Cai W. Tumor-targeted drug delivery with aptamers. Curr. Med. Chem. 2011, 18:4185-4194.
155. Zhu G., Ye M., Donovan M.J., Song E., Zhao Z., Tan W. Nucleic acid aptamers: an emerging frontier in cancer therapy. Chem. Commun. (Camb.) 2012, 48:10,472-10,480.
156. Zhu J., Huang H., Dong S., Ge L., Zhang Y. Progress in aptamer-mediated drug delivery vehicles for cancer targeting and its implications in addressing chemotherapeutic challenges. Theranostics 2014, 4:931-944.
157. Zichel R., Chearwae W., Pandey G.S., Golding B., Sauna Z.E. Aptamers as a sensitive tool to detect subtle modifications in therapeutic proteins. PLoS One 2012, 7.